Inhibition of MEK to Treat Cancer, Focussing on Melanoma

As part of ESMO's continuous commitment to offering beneficial educational material relevant to your work and practice in order to receive your certificate, please complete the Evaluation Survey, which will take approximately 5 minutes. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did your undertaking of this V-Learning module provide an understanding of the RAS-RAF-MEK-ERK pathway and related signaling, as well as oncogenic drivers within the pathway? (1-not at all; 5-a lot)

2. Did this V-Leaning module help you understand which driver mutations may be affected by MEK inhibition in patients with metastatic melanoma? (1-not at all; 5-a lot)

3. Did it describe novel therapeutic agents – MEK inhibitors, their mechanism of action, results from recent clinical studies and side-effects? (1-not at all; 5-a lot)

4. Please, provide your overall rating of the quality of the education offered by this V-Learning module. (1-not at all; 5-a lot)

5. How would you rate the interactivity level offered in the V-Learning material? (1-not at all; 5-a lot)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-a lot)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-a lot)

8. If you would like to add your personal comments or make suggestions to improve future ESMO V-Learning material, please write in the box below: